New Cancer Vaccine Cuts Melanoma Recurrence by 49%

A personalized mRNA vaccine combined with immunotherapy reduced melanoma recurrence or death by nearly half over five years.

The breakthrough treatment, developed by Merck and Moderna, teaches the immune system to recognize and attack cancer cells.